LSTA (Lisata Therapeutics) Stock Based Compensation: $1.06 Mil (TTM As of Mar. 2026)


LSTA Lisata Therapeutics Inc LSTA
19 GF Score
Price $3.25
! 4 Warning Signs
View Full Analysis

What is Lisata Therapeutics Stock Based Compensation?

Lisata Therapeutics LSTA +0.78% 19 Stock Based Compensation is $1.06 Mil as of Mar. 2026. GuruFocus rates LSTA with a GF Score™ of 19/100. The stock has 4 warning signs investors should review.

Lisata Therapeutics's Stock Based Compensation for the three months ended in Mar. 2026 was $0.36 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was $1.06 Mil.

Lisata Therapeutics Stock Based Compensation Related Terms

Lisata Therapeutics Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Lisata Therapeutics's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lisata Therapeutics Stock Based Compensation Chart

Lisata Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.01 2.64 2.04 1.65 1.23

Lisata Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.53 0.24 0.23 0.23 0.36
LSTA
19GF Score
Lisata Therapeutics Inc LSTA
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lisata Therapeutics Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.06 Mil.

What does a Stock Based Compensation of $1.06 Mil mean?
Lisata Therapeutics (LSTA) has a Stock Based Compensation of $1.06 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Lisata Therapeutics and its competitors.
Is Lisata Therapeutics' Stock Based Compensation too high?
Lisata Therapeutics' current Stock Based Compensation is $1.06 Mil. Overall, Lisata Therapeutics has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Lisata Therapeutics' Stock Based Compensation compare to SGMO and NNVC?
Lisata Therapeutics' Stock Based Compensation of $1.06 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Lisata Therapeutics and its competitors. Lisata Therapeutics's current Stock Based Compensation is $1.06 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lisata Therapeutics stock overvalued right now?
Lisata Therapeutics (LSTA) has a current Stock Based Compensation of $1.06 Mil. The current Stock Based Compensation is $1.06 Mil. Lisata Therapeutics' overall GF Score™ is 19/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Lisata Therapeutics (LSTA), the current Stock Based Compensation is $1.06 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lisata Therapeutics Business Description

Other Exchanges 0HS8:UK8NE:Germany
Address 110 Allen Road, 2nd Floor, Basking Ridge, NJ, USA, 07920
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.
19GF Score

Get the complete analysis for LSTA

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.25
Price